Apollo Capital Releases Investor Presentation Highlighting Plan to Make MediPharm Labs the World’s Leading International Medical Cannabis Company

Core Viewpoint - Apollo Technology Capital Corporation, a significant shareholder of MediPharm Labs Corp., has presented a plan aimed at revitalizing the company and enhancing shareholder value [1][6]. Shareholder Engagement - Shareholders are encouraged to vote for Apollo Capital's six director nominees using the "Gold Card" and to disregard MediPharm's "Green Card" [2][3]. - The communication emphasizes the urgency for shareholders to act in order to protect their investments [2][3]. Ownership and Influence - Apollo Capital, through its subsidiary Nobul Technologies Inc., owns approximately 3% of MediPharm's common shares, totaling 12,491,500 shares [4][6]. - The company is actively seeking to influence the board of directors through its proxy solicitation efforts [11]. Action Plan - Apollo Capital has outlined a commitment to execute an aggressive action plan aimed at increasing MediPharm's share price by over 10 times and preventing insolvency [6]. - The plan includes measures to address excessive executive compensation and rectify three years of value-destructive actions [6]. Legal and Regulatory Compliance - Apollo Capital has filed an amended dissident information circular in compliance with Canadian corporate and securities laws, detailing their director nominees and the rationale behind their actions [5][7]. - Shareholders are advised to read the amended circular carefully as it contains crucial information regarding the upcoming annual meeting [8].